Lineage Cell Therapeutics

Lineage Cell Therapeutics EBITDA per Share

The EBITDA per Share of Lineage Cell Therapeutics (LCTX) as of Oct 31, 2026 is -0.09 USD. In the previous year, EBITDA per Share was -0.11 USD — a change of -11.69% (higher).

EBITDA per Share

-0.09USD

YoY

-11.69%

Last updated:

EBITDA per Share of Lineage Cell Therapeutics is 2025 -0.09 USD. EBITDA per Share of Lineage Cell Therapeutics was 2024 -0.11 USD. It decreases by -11.69% higher compared to the previous year.

The Lineage Cell Therapeutics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.31 USD
Jan 1, 2019
-0.25 USD
Jan 1, 2020
-0.17 USD
Jan 1, 2021
-0.29 USD
Jan 1, 2022
-0.13 USD
Jan 1, 2023
-0.14 USD
Jan 1, 2024
-0.11 USD
Jan 1, 2025
-0.09 USD
The Lineage Cell Therapeutics EBITDA per Share history
YEAREBITDA per ShareYoY
-0.09USD-11.69%
-0.11USD-24.88%
-0.14USD+8.18%
-0.13USD-54.90%
-0.29USD+73.68%
-0.17USD-31.62%
-0.25USD-21.05%
-0.31USD+1.68%
-0.31USD-46.56%
-0.57USD-21.17%
-0.73USD+11.95%
-0.65USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lineage Cell Therapeutics Stock analysis

What does Lineage Cell Therapeutics do? Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lineage Cell Therapeutics stock

EBITDA per Share of Lineage Cell Therapeutics is -0.09 USD in 2025.

EBITDA per Share of Lineage Cell Therapeutics changed from -0.11 USD to -0.09 USD, representing a -11.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Lineage Cell Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lineage Cell Therapeutics

All Key Metrics — Lineage Cell Therapeutics